CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life
science partner for data-driven answers in rare and
neurodegenerative diseases, and the Laboratory of Human Genetics of
Infectious Diseases (the “Lab”) at Institut Imagine today announced
a strategic research collaboration to improve health outcomes for
rare disease patients by accelerating and de-risking drug discovery
and clinical development.
As part of the collaboration, CENTOGENE and the Lab will
leverage the CENTOGENE Biodatabank, which contains over 70 million
unique genetic variants collected from more than 800,000 patients
from over 120 countries – providing valuable and unparalleled
insights into the role that specific genes play in disease.
Together, CENTOGENE and the Lab will jointly agree on future
research projects that will integrate multiomics and bioinformatics
to analyze this highly diverse data to discover and validate novel
genetic and biochemical targets that can be used for future
development of rare disease therapies. By proving and validating
the relevance of a target to disease and that modulating it will
have the desired outcome, drug discovery and development can be
significantly accelerated and de-risked. Specific targets of the
collaboration have not been disclosed.
“Our mission is to gain a better understanding of the human
genetic and immunological determinants of rare and common
infectious diseases,” said Dr. Jean-Laurent Casanova, Head of the
Laboratory of Human Genetics of Infectious Diseases. “By working
together with CENTOGENE to leverage deep multiomic and multiethnic
insights, we will be able to accelerate more precise treatment
options and ultimately improve patient health outcomes.”
“At CENTOGENE, we are committed to delivering data-driven,
life-changing answers to accelerate and de-risk drug discovery,
development, and commercialization. By leveraging our highly
diverse insights, multiomic technologies, and rare disease
expertise, we are able to qualitatively make a difference in the
success of research and early clinical development,” said Prof.
Peter Bauer, CENTOGENE’s Chief Medical and Genomic Officer. “In
teaming up with the Laboratory of Human Genetics of Infectious
Diseases at Institut Imagine, we will be able to collaboratively
contribute to some of the world’s leading research projects to
transform data into life-saving therapeutics for patients around
the world.”
With more than 350 million people worldwide affected by over
7,000 rare diseases, approximately 95% of which do not have an
available treatment, rare disease patients are facing some of the
highest unmet medical needs. Progress towards the development of
new therapies and cures in rare diseases is hindered by several
factors:
- A lack of disease understanding compounded by small patient
population
- Difficulties in correctly diagnosing and identifying patients
for trials
- A lack of clearly defined clinical endpoints
- Complexities around leveraging real-world data
By combining expertise, the collaboration will support
end-to-end, data-driven drug discovery and clinical development to
enable better health outcomes for rare disease patients.
“Since its creation in 2007, Institut Imagine has been forming
partnerships with the leading healthcare players to combine
resources and transform care for patients around the world,” said
Stanislas Lyonnet, Director of Institut Imagine. “Institut Imagine
is excited to see this partnership between the Laboratory of Human
Genetics of Infectious Diseases and CENTOGENE to advance research
and make an impact for patients for years to come.”
Dr. Vivien Béziat, Researcher at the Laboratory of Human
Genetics of Infectious Diseases, and Dr. Christian Ganoza, Senior
Scientist at CENTOGENE, are project leads for this
collaboration.
About Institut Imagine
Located on the campus of the Necker-Enfants malades hospital,
the Institut Imagine is a world leader in research, care and
teaching on genetic diseases. Its unique architecture, designed by
Jean Nouvel and Bernard Valéro, brings together 1,000 researchers,
physicians, teacher-researchers, engineers and health care
personnel in a single location to work with patients, with the
ambition of accelerating research and diagnosis and therapeutic
innovation to change the lives of families affected by genetic
diseases. The Institut Imagine has been certified “Institut
hospitalo universitaire” (IHU), in 2011 and 2019 and a “Institut
Carnot”, in 2020. It is supported by six founding members,
including AP-HP, Inserm and Université Paris Cité, as well as by
private partners and patrons. Every day in France, 64 babies are
born with a genetic disease. Nearly 8,000 genetic diseases affect
more than 3 million people, of which nearly one in two is
undiagnosed and more than 8 in 10 have no dedicated treatment.
Faced with this public health emergency, the challenge is twofold:
to diagnose and to cure.
www.institutimagine.org
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “is set to,” “potential,” “predict,” “objective” and
similar expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, changes in our mix of customers and partners and
their order practices with respect to our products and solutions,
our reliance on third parties and collaboration partners, including
our ability to manage growth, execute our business strategy and
enter into new client relationships, our dependency on the rare
disease industry, our ability to manage international expansion,
our reliance on key personnel, our reliance on intellectual
property protection, fluctuations of our operating results due to
the effect of exchange rates, our ability to streamline cash usage,
our continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, and our
ability to continue as a going concern, or other factors. For
further information on the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on May 16, 2023, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and CENTOGENE
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications
Press@centogene.com
Lennart StreibelInvestor Relations IR@centogene.com
Institut Imagine
Juliette Arcos DeslogesHavas Red Health
juliette.desloges@havas.com +33 06 07 38 35 35
Pablo Alvarez Havas Red Health
pablo.alvarez@havas.com +33 07 89 45 79 08
Anne LenoirInstitut Imagineanne.lenoir@institutimagine.org+33 01
42 75 47 22
Marie de BazelaireInstitut
Imaginemarie.de-bazelaire@institutimagine.org
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024